Cybin Inc. (NASDAQ:HELP) Receives Average Recommendation of "Buy" from AnalystsMarket Beat·Jul 27 at 09:14 AMHELP+2.91%BAC+1.08%
Helus Pharma Fast-Tracks Phase 3 Enrollment for MDD Drug HLP003Tip Ranks·Jul 21 at 04:51 PMHELP+2.91%
Big Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real TimePR Newswire·Jul 17 at 07:50 AMATAI0.00%HELP+2.91%
Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions | LLY Stock NewsStockTitan·Jul 15 at 09:45 PMLLY-4.55%ATAI0.00%
UnitedHealth, Abbott Laboratories And 3 Stocks To Watch Heading Into Thursdaybenzinga_article·Jul 16 at 02:18 AMABT-2.21%UNH+0.21%
Cybin publishes corporate presentation on HLP003, deuterated serotonergic agonist for major depressive disorderPUBT·Jun 29 at 07:23 AMHELP+2.91%
HELP: HLP003 and HLP004 show strong Phase 2 efficacy and safety, advancing toward pivotal trialsQuartr·Jun 29 at 07:03 AMHELP+2.91%
Helus Pharma Reports Recent Business Highlights and Fiscal Year 2026 Financial ResultsUnusual Whales·Jun 29 at 06:40 AMHELP+2.91%
Helus Pharma Reports Recent Business Highlights and Fiscal Year 2026 Financial Results | HELP Stock NewsStockTitan·Jun 28 at 10:40 PMHELP+2.91%
Cybin (HELP) As Phase 3 Enrollment Progresses, The Undervalued Narrative HoldsSimplywall·Jun 28 at 02:59 PMHELP+2.91%
A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This YearUnusual Whales·Jun 26 at 08:32 AMHELP+2.91%
Helus Pharma™ Announces Closing of US$50 Million Underwritten Offering | HELP Stock NewsStockTitan·Jun 25 at 12:27 AMHELP+2.91%BARC
